Laboratory for Diagnostic of Zoonoses and World Health Organization (WHO) Center, Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia.
Front Cell Infect Microbiol. 2021 Jul 1;11:696337. doi: 10.3389/fcimb.2021.696337. eCollection 2021.
Although anti-TBE vaccines are highly effective, vaccine breakthrough (VBT) cases have been reported. With increasing evidence for immune system involvement in TBE pathogenesis, we characterized the immune mediators reflecting innate and adaptive T and B cell responses in neurological and convalescent phase in VBT TBE patients. At the beginning of the neurological phase, VBT patients have significantly higher serum levels of several innate and adaptive inflammatory cytokines compared to healthy donors, reflecting a global inflammatory state. The majority of cytokines, particularly those associated with innate and Th1 responses, are highly concentrated in CSF and positively correlate with intrathecal immune cell counts, demonstrating the localization of Th1 and proinflammatory responses in CNS, the site of disease in TBE. Interestingly, compared to unvaccinated TBE patients, VBT TBE patients have significantly higher CSF levels of VEGF-A and IFN-β and higher systemic levels of neutrophil chemoattractants IL-8/CXCL8 and GROα/CXCL1 on admission. Moreover, serum levels of IL-8/CXCL8 and GROα/CXCL1 remain elevated for two months after the onset of neurological symptoms, indicating a prolonged systemic immune activation in VBT patients. These findings provide the first insights into the type of immune responses and their dynamics during TBE in VBT patients. An observed systemic upregulation of neutrophil derived inflammation in acute and convalescent phase of TBE together with highly expressed VEGF-A could contribute to BBB disruption that facilitates the entry of immune cells and supports the intrathecal localization of Th1 responses observed in VBT patients.
尽管抗 TBE 疫苗具有高度的有效性,但仍有疫苗突破(VBT)的病例报告。鉴于免疫系统在 TBE 发病机制中的作用证据不断增加,我们对 VBT TBE 患者的神经和恢复期的先天和适应性 T 和 B 细胞反应的免疫介质进行了特征描述。在神经发病初期,VBT 患者的血清中几种先天和适应性炎症细胞因子水平明显高于健康供体,反映出全身性炎症状态。大多数细胞因子,特别是与先天和 Th1 反应相关的细胞因子,在 CSF 中高度浓缩,并与鞘内免疫细胞计数呈正相关,这表明 Th1 和促炎反应在 TBE 疾病的中枢神经系统中定位。有趣的是,与未接种疫苗的 TBE 患者相比,VBT TBE 患者在发病时的 CSF 中 VEGF-A 和 IFN-β 水平以及全身性中性粒细胞趋化因子 IL-8/CXCL8 和 GROα/CXCL1 水平明显更高。此外,血清中 IL-8/CXCL8 和 GROα/CXCL1 的水平在神经系统症状出现后两个月仍保持升高,表明 VBT 患者存在长期的全身性免疫激活。这些发现首次提供了有关 VBT 患者 TBE 期间免疫反应类型及其动态变化的见解。在 TBE 的急性期和恢复期观察到的中性粒细胞衍生炎症的全身性上调,以及高度表达的 VEGF-A,可能导致 BBB 破坏,从而有利于免疫细胞的进入,并支持在 VBT 患者中观察到的 Th1 反应的鞘内定位。